A Nonsteroidal Novel Formulation Targeting Inflammatory and Pruritus-Related Mediators Modulates Experimental Allergic Contact Dermatitis.

Autor: Gordon WC; Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA., López VG; Diater, Av. Gregorio Peces Barba, Madrid, Spain., Bhattacharjee S; Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA., Gil DR; Diater, Av. Gregorio Peces Barba, Madrid, Spain., Díaz JA; Diater, Av. Gregorio Peces Barba, Madrid, Spain., de la Losa FP; Diater, Av. Gregorio Peces Barba, Madrid, Spain., Peláez RP; Diater, Av. Gregorio Peces Barba, Madrid, Spain., Ferrer CT; Farmalider, Calle La Granja, Madrid, Spain., Bacchini GS; Ferrer, Av. Diagonal 549, Barcelona, Spain., Jun B; Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA., Varoqui H; Ochsner North Shore Dermatology Practice, Slidell, LA, USA., Bazan NG; Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA. nbazan@lsuhsc.edu.
Jazyk: angličtina
Zdroj: Dermatology and therapy [Dermatol Ther (Heidelb)] 2018 Mar; Vol. 8 (1), pp. 111-126. Date of Electronic Publication: 2018 Feb 16.
DOI: 10.1007/s13555-018-0223-8
Abstrakt: Introduction: A major clinical challenge in treating allergic contact dermatitis (ACD) is that the first line of treatment is based on the use of corticosteroids. In this study, we aimed to develop a formulation that is devoid of steroids.
Methods: We used mouse ears treated with dinitrofluorobenzene (DNFB) to induce ACD. The efficacy of the test formulation to ameliorate and to prevent induced ACD was determined.
Results: To treat this experimentally induced ACD, we developed a formulation containing BIPxine (a mixture of Rosa moschata and Croton lechleri (antioxidants) and Aloe vera and D-panthenol (moisturizers), and hydroglycolic solutions of disodium cromoglycate. Our results show that clear inhibition of ACD took place. The target of this formulation was PAR-2, TRPV4, and other mediators of the inflammatory and pain responses. However, this formulation must be evaluated in other models besides the mouse to confirm its effectiveness.
Conclusion: The formulation presented here may provide new ACD therapies that do not involve the use of corticosteroids.
Databáze: MEDLINE
Externí odkaz: